CR20230366A - Fracciones que prolongan la semivida y métodos de uso de estas - Google Patents

Fracciones que prolongan la semivida y métodos de uso de estas

Info

Publication number
CR20230366A
CR20230366A CR20230366A CR20230366A CR20230366A CR 20230366 A CR20230366 A CR 20230366A CR 20230366 A CR20230366 A CR 20230366A CR 20230366 A CR20230366 A CR 20230366A CR 20230366 A CR20230366 A CR 20230366A
Authority
CR
Costa Rica
Prior art keywords
same
methods
extending moieties
life extending
moieties
Prior art date
Application number
CR20230366A
Other languages
English (en)
Spanish (es)
Inventor
Josef George Heuer
Stacey Lynn Lee
Petra Verdino
Andrea Ferrante
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20230366A publication Critical patent/CR20230366A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CR20230366A 2021-02-02 2022-02-01 Fracciones que prolongan la semivida y métodos de uso de estas CR20230366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144696P 2021-02-02 2021-02-02
PCT/US2022/014728 WO2022169757A1 (en) 2021-02-02 2022-02-01 Half-life extending moieties and methods of using the same

Publications (1)

Publication Number Publication Date
CR20230366A true CR20230366A (es) 2023-10-03

Family

ID=80735776

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230366A CR20230366A (es) 2021-02-02 2022-02-01 Fracciones que prolongan la semivida y métodos de uso de estas

Country Status (18)

Country Link
US (1) US20240316154A1 (cg-RX-API-DMAC10.html)
EP (1) EP4288452A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024506145A (cg-RX-API-DMAC10.html)
KR (1) KR20230137342A (cg-RX-API-DMAC10.html)
CN (1) CN116802209A (cg-RX-API-DMAC10.html)
AU (1) AU2022217754A1 (cg-RX-API-DMAC10.html)
CA (1) CA3204225A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023002285A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023010002A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230366A (cg-RX-API-DMAC10.html)
DO (1) DOP2023000149A (cg-RX-API-DMAC10.html)
EC (1) ECSP23058246A (cg-RX-API-DMAC10.html)
IL (1) IL304219A (cg-RX-API-DMAC10.html)
JO (1) JOP20230173A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009006A (cg-RX-API-DMAC10.html)
PE (1) PE20240233A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022169757A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202306754B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260109751A1 (en) * 2022-12-30 2026-04-23 Eli Lilly And Company Methods of dulaglutide purification using hydrophobic interaction chromatography
EP4731669A2 (en) * 2023-06-21 2026-04-29 Eli Lilly and Company Compounds for the delivery of granulin across the blood brain barrier

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2259802A1 (en) * 2008-03-31 2010-12-15 Glaxo Group Limited Drug fusions and conjugates
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2015231170B2 (en) * 2014-03-20 2019-10-03 Bristol-Myers Squibb Company Serum albumin-binding fibronectin type III domains
WO2018104444A1 (en) * 2016-12-07 2018-06-14 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
EP3807311A4 (en) * 2018-04-24 2022-01-26 National Research Council of Canada SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法

Also Published As

Publication number Publication date
PE20240233A1 (es) 2024-02-16
ECSP23058246A (es) 2023-09-29
CO2023010002A2 (es) 2023-09-08
JP2024506145A (ja) 2024-02-09
KR20230137342A (ko) 2023-10-04
CN116802209A (zh) 2023-09-22
ZA202306754B (en) 2025-02-26
JOP20230173A1 (ar) 2023-07-30
CL2023002285A1 (es) 2024-02-23
AU2022217754A1 (en) 2023-07-27
DOP2023000149A (es) 2023-09-15
CA3204225A1 (en) 2022-08-11
EP4288452A1 (en) 2023-12-13
WO2022169757A1 (en) 2022-08-11
MX2023009006A (es) 2023-08-08
CL2025003008A1 (es) 2025-12-19
US20240316154A1 (en) 2024-09-26
IL304219A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
ZA202403923B (en) Heterocyclic compounds as immunomodulators
PH12022552739A1 (en) Fused tricyclic kras inhibitors
PH12022550165A1 (en) Interleukin-2 agents and uses thereof
ZA202002094B (en) Trispecific proteins and methods of use
MY197635A (en) Benzooxazole derivatives as immunomodulators
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MY197280A (en) Heterocyclic compounds as immunomodulators
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
CR20220656A (es) Unión de anticuerpos multiespecíficos a bcma
MX2023006599A (es) Metodos de uso de agentes de interleucina-2.
ZA202211464B (en) Tetrahydroisoquinoline compounds as nrf2 activators
EP4252755A3 (en) Therapeutic compounds
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2023008598A (es) Agentes de interleuquina-2 y usos de los mismos.
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2025007184A (es) Triterpenoides sinteticos heteroaromaticos sustituidos polarmente en c17, y metodos de uso de los mismos
ZA202306754B (en) Half-life extending moieties and methods of using the same
SA522432999B1 (ar) C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها
PH12019500198A1 (en) Compounds and compositions and uses thereof
ZA202211465B (en) Tetrahydroisoquinoline compounds as nrf2 activators